Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children (Abilify)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by University of Medicine and Dentistry New Jersey.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
University of Medicine and Dentistry New Jersey
Information provided by:
University of Medicine and Dentistry New Jersey
ClinicalTrials.gov Identifier:
NCT00468130
First received: April 30, 2007
Last updated: November 5, 2009
Last verified: November 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.
(2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity.
The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.
| Condition | Intervention |
|---|---|
|
Autism |
Drug: Aripiprazole Other: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children |
Resource links provided by NLM:
Further study details as provided by University of Medicine and Dentistry New Jersey:
Primary Outcome Measures:
- Clinical Global Impression Improvement (CGI-AD) [ Time Frame: Administered weekly ] [ Designated as safety issue: No ]
- Aberrant Behavior Checklist [ Time Frame: Administered weekly ] [ Designated as safety issue: No ]
- Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: Administered every 4 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | November 2009 |
| Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Aripiprazole
Subjects in the experimental group will receive Aripiprazole
|
Drug: Aripiprazole
Subjects under 40 kg will be started on 2.5mg per day of aripiprazole or placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Other Name: Abilify
|
|
Placebo Comparator: Placebo
Subjects in the control group will receive placebo
|
Other: Placebo
Subjects in the control group will receive placebo in the same dosage as the active drug
|
Detailed Description:
Aripiprazole is an atypical antipsychotic medication which is currently approved for the treatment of schizophrenia in adults. Multiple clinical trials in both children and adults have shown the effectiveness in the treatment of autism with medications like Aripiprazole. This study aims at assessing the effect of aripiprazole vs. placebo treatment on symptoms of irritability and aggression associated with autism, as well as the effect on the global severity of child and adolescent autistic disorder. Children or adolescent outpatients, with age ranges from 5-17, will be enrolled into an 8-week placebo controlled, double blind treatment study. During the 8 weeks, patients will be monitored by the treating psychiatrist. Study assessments will be administered at designated time points.
Eligibility| Ages Eligible for Study: | 5 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Meets DSM-IV, ADI-R criteria for autistic disorder.
- Age 5-17 years.
- Outpatients
- Parent or legal guardian willing to sign informed consent.
Exclusion Criteria:
- Subject has been diagnosed with a psychotic disorder (such as schizophrenia) or a mood disorder, including depression or bipolar disorder (manic depression).
- Subject has caused visible harm to him/herself.
- Subject has an active seizure disorder or epilepsy (seizures within the past year).
- Subject has an unstable medical illness, including heart disease.
- Subject has experienced brain injury.
- Subject has a history of diabetes.
- Subject reports significant improvement of autism symptoms and behaviors to current medication or other therapies.
- Subject has a history of prior treatment with Aripiprazole of 5 mg/day or higher for 6 weeks.
- Subject lives in a far away area and/or does not have regular access to transportation to the clinical facility.
- Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00468130
Locations
| United States, New Jersey | |
| Department of Child and Adolescent Psychiatry, University Behavioral Health Care Building | |
| Piscataway, New Jersey, United States, 08854 | |
Sponsors and Collaborators
University of Medicine and Dentistry New Jersey
Investigators
| Principal Investigator: | Sherie L. Novotny, MD | Child and Adolescent Psychiatry, UMDNJ |
More Information
Additional Information:
Publications:
Aman M, Smgh N, Stewart A, Field C. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.Am J Ment Defic, 1985a;89(5):485 491 Campbell M, et al, Neuroleptic related dyskinesias in autistic children: a prospective longitudinal study, J Am Acad Child Adolesc Psychiatry 1997; 36(6): 835 43. Fomboime E. The epidemiology of autism: a review. Psychological Medicine, 1999; 29:769 786. Guy W. ECDEU assessment manual for psychopharmacology. Revised. NTMH Publication DHEW Publ No (adm.) 76 388. Bethesda, MD: National Institute of Mental Health, 1976; 217 222. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open label study. J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):685 93. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, J Clin Psychiatry. 2001;62(l1).
| Responsible Party: | Dr.Sherie Novotny, UMDNJ-RWJMS |
| ClinicalTrials.gov Identifier: | NCT00468130 History of Changes |
| Other Study ID Numbers: | 0220055441 |
| Study First Received: | April 30, 2007 |
| Last Updated: | November 5, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Medicine and Dentistry New Jersey:
|
Aggression Irritability Global autism severity |
Additional relevant MeSH terms:
|
Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders Aripiprazole Antipsychotic Agents Tranquilizing Agents |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 16, 2013